The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1482
November 23, 2015
View Complete Issue         Table of Contents 2019 
Bexsero - A Second Serogroup B Meningococcal Vaccine
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Bexsero - A Second Serogroup B Meningococcal Vaccine
November 23, 2015 (Issue: 1482)
The FDA has approved Bexsero (Novartis/GSK), a vaccine that protects against invasive meningococcal disease caused by Neisseria meningitidis serogroup B. It is the second serogroup B meningococcal vaccine to be approved in the US; Trumenba was...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Bexsero - A Second Serogroup B Meningococcal Vaccine
Article code: 1482b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.